{
    "clinical_study": {
        "@rank": "156245", 
        "acronym": "ITP", 
        "arm_group": [
            {
                "arm_group_label": "Rituximab A group", 
                "arm_group_type": "Experimental", 
                "description": "375mg/m2 for once"
            }, 
            {
                "arm_group_label": "Rituximab B group", 
                "arm_group_type": "Active Comparator", 
                "description": "100mg/week for four weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "A comparative study with rituximab (100 mg weekly for 4 weeks and 375mg/m2 for once) shows\n      low dose rituximab may be a useful alternative therapy in patients with ITP.The aim of this\n      study is to compare the efficacy and tolerability of two different regimens of low doses\n      rituximab for the treatment of adult patients with ITP."
        }, 
        "brief_title": "Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia", 
        "completion_date": {
            "#text": "October 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Immune Thrombocytopenic Purpura", 
        "condition_browse": {
            "mesh_term": [
                "Purpura", 
                "Purpura, Thrombocytopenic", 
                "Thrombocytopenia", 
                "Purpura, Thrombocytopenic, Idiopathic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Hundreds of Patients without infection (age 18 to 60 years old) developed Chronic ITP. All\n      patients will be enrolled in this study and will be randomly assigned to receive 100 mg\n      rituximab weekly for 4 weeks (group A) or a single dose of 375 mg/m2 rituximab (group B).\n      After treatment all patients will be followed for two years. During observation platelet\n      count and B lymphocyte will be detected every month."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult chronic ITP, age 18 to 60\n\n        Exclusion Criteria:\n\n          -  pregnant woman with ITP; liver disease and kidney disease;  allergy to rituximab"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01719692", 
            "org_study_id": "low dose rituximab for ITP"
        }, 
        "intervention": {
            "arm_group_label": [
                "Rituximab A group", 
                "Rituximab B group"
            ], 
            "intervention_name": "Rituximab", 
            "intervention_type": "Drug", 
            "other_name": "Trade names Rituxan and MabThera"
        }, 
        "intervention_browse": {
            "mesh_term": "Rituximab"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "contact": {
                "email": "zhangleipumc@163.com", 
                "last_name": "Lijun Liu, Master", 
                "phone": "86-22-2390240"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300020"
                }, 
                "name": "Hospital of Blood disease"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Prospective Multi-center Randomized Controlled Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia", 
        "overall_contact": {
            "email": "zlpumc@hotmail.com", 
            "last_name": "RENCHI YANG, Dr", 
            "phone": "86-22-23909122"
        }, 
        "overall_official": {
            "affiliation": "Hospital of Blood disease", 
            "last_name": "RENCHI YANG, Dr", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Compare the platelet count between two groups given different doses of Rituximab.", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be followed for 6 months after Rituximab treatment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01719692"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Institute of Hematology & Blood Diseases Hospital", 
            "investigator_full_name": "Renchi Yang", 
            "investigator_title": "Thrombosis and Hemostasis Center", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Institute of Hematology & Blood Diseases Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "National Natural Science Foundation of China", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Institute of Hematology & Blood Diseases Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}